Sera Prognostics Rises on Positive Topline Results from Preterm Birth Treatment Study
The Pregnancy Company®, Sera Prognostics (Nasdaq: SERA), has announced that positive data from its AVERT PRETERM TRIAL has been published in the international, peer-reviewed journal, Diagnostics. Sera rose to the top of the PRISM Emerging Women’s Health Index following the news, with a share price increase of almost 20%, bringing the stock to $6.91.
The company is evaluating the health benefit to babies when pregnancies are screened with Sera’s PreTRM® test-and-treat strategy. Studies have demonstrated statistically and clinically significant improvement in neonatal health outcomes and hospital length-of-stay.
Commenting on the news, Zhenya Lindgardt, President and CEO of Sera Prognostics, said, “The AVERT PRETERM TRIAL results demonstrate for the first time that the health of babies can be improved in asymptomatic pregnant mothers without typical risk factors by the combination of biomarkers for spontaneous preterm birth risk and targeted interventions.
“We are delighted to have published these clinically significant results in Diagnostics. We are now actively engaged in analyzing our final PRIME study results to continue to enrich an already broad portfolio of evidence for our PreTRM® test-and-treat strategy in improving maternal and neonatal care while reducing healthcare costs.”
More than one in ten infants is born prematurely in the United States. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss.
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera’s mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests and digital tools focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera’s precision medicine PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is headquartered in Salt Lake City, Utah.
